Clinical outcome using a modified treat-and-extend protocol for neovascular age-related macular degeneration

Author:

Vofo Brice NguediaORCID,Cnaany YaacovORCID,Chowers I

Abstract

AimTo compare outcome between patients treated using a modified treat-and-extend (mT&E) protocol and patients treated using a conventional T&E protocol.MethodsA retrospective cohort study of two groups of treatment-naïve neovascular age-related macular degeneration patients within a single centre were evaluated. One group treated using the conventional T&E protocol, with visual acuity, dilated fundus examination (DFE) and optical coherence tomography (OCT) performed at each visit. The second group treated using the mT&E protocol in which visual acuity and DFE were performed only every three visits. The main outcome measures were time spent per clinical visit, visual and anatomical outcomes measured for 36 months.ResultsThe T&E and mT&E groups included 135 eyes in 116 patients and 119 eyes in 94 patients, respectively, with similar baseline characteristics. At 36 months, the number of injections administered (7.9±2.9 vs 8.1±2.3 injections, respectively; p=0.55), the percentage of eyes that gained ≥15 Early Treatment for Diabetic Retinopathy Study (ETDRS) letters (23% vs 25.2%, respectively; p=0.39) and the percentage of eyes that lost ≥15 ETDRS letters (21.5% vs 17.7%; p=0.43, respectively) were similar between the T&E and mT&E groups. However, waiting and contact time were reduced during the OCT-only visits compared with the full visits, with an average of 41 min saved per patient encounter.ConclusionsBoth protocols yielded similar visual and anatomical outcomes. However, the mT&E protocol reduced the number of full visits, with considerably less time spent at the clinic.

Funder

Israel Science Foundation

Publisher

BMJ

Subject

Ophthalmology

Reference27 articles.

1. Five-Year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials;Maguire;Ophthalmology,2016

2. Ranibizumab for Neovascular Age-Related Macular Degeneration

3. Long-Term outcome of neovascular age-related macular degeneration: association between treatment outcome and major risk alleles;Vofo;Br J Ophthalmol,2022

4. 2018 update on intravitreal injections: Euretina expert consensus recommendations;Grzybowski;Ophthalmologica,2018

5. The Royal College of Ophthalmologists . The way forward. options to help meet demand for the current and future care of patients with eye disease. age-related macular degeneration and diabetic retinopathy. London The Royal College of Ophthalmologists; 2015. https://www.rcophth.ac.uk/wp-content/uploads/2015/10/RCOphthThe-Way-Forward-AMD-300117.pdf [Accessed 1 Sep 2021].

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3